News | November 17, 2021

Sense Announces Increase Of Series B To $65M To Support Launch Of Rapid, Point-Of-Care Molecular Diagnostic

BOSTON & OXFORD, ENGLAND--(BUSINESS WIRE)--

Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced that after achieving several key milestones this year, the company’s Series B funding round has been increased to $65M, an additional $15 million from prior commitments. The round was led by existing investor Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, Inc.

Funds from the round will be used to support the anticipated U.S. and European commercial launch of Sense’s COVID-19 Test on the company’s Veros™ instrument-free molecular platform. Sense recently completed an extensive, prospective, multi-site clinical study that supported the company’s Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA) for marketing clearance of the Veros COVID-19 Test. Veros has the potential to be the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results within 15 minutes.

“Since our initial investment in Sense, we have witnessed the huge potential of the Veros platform and its promise to transform healthcare – and specifically its application for COVID-19 testing,” said Brett Chugg, senior managing director, Koch Disruptive Technologies. “We are enthusiastic about Sense’s future and its potential to change the way medical providers and patients approach healthcare, and we look forward to supporting the company as it seeks EUA and launches its first test.”

Globally, there have been over 244 million total confirmed cases of COVID-19, including more than 4.9 million deaths.i Currently, COVID-19 infection is often confirmed by a laboratory-based molecular method. While current methods produce highly accurate results, they have many limitations including high costs, time delays, and requirements for expensive equipment and training. This can make it difficult for providers to reach everyone, especially under-served and under-resourced communities.

Unconstrained by an instrument or reader, the Veros platform has the potential to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Using a proprietary rapid molecular amplification technology, Veros aims to deliver instrument-free, PCR-quality laboratory results directly to users within minutes.

“People with suspected COVID-19 infection and other deadly and costly diseases must know quickly whether they are infected. Our aim is to overcome the barriers of current diagnostic testing with an easy-to-use, rapid, disposable molecular test,” said Timothy I. Still, CEO of Sense. “This increased funding by our current investors combined with our EUA submission are two important milestones in getting our solution into the hands of clinicians. We feel fortunate to have such supportive and reliable partners and look forward to further advancing the Veros platform toward commercialization in 2022, starting with the Veros COVID-19 test.”

About Sense Biodetection

Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros™ product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health, Sense is growing rapidly as it prepares to launch Veros™ COVID-19 and build a portfolio of additional tests for other diseases.

For more information, visit https://sense-bio.com/ and follow the company on Twitter at @sensedx1 and on LinkedIn at @Sense Biodetection Ltd.

About Koch Disruptive Technologies

Koch Disruptive Technologies (KDT) is a unique investment firm, focused on empowering founders to create a could-be world. KDT provides a flexible, multi-stage investment approach which includes both traditional venture and growth stages. We work with principled entrepreneurs who are building transformative companies, disrupting the status quo, and creating new platforms. KDT is a subsidiary of Koch Industries, one of the largest privately held companies in the world with $115 billion in revenue and operating in more than 70 countries. KDT helps its partners unlock their full potential by bringing Koch’s capabilities and network to them, structuring unique capital solutions, and embracing a long-term, mutual benefit mindset.

For more information, visit www.kochdisrupt.com.

 


i World Health Organization. WHO coronavirus (COVID-19) dashboard. World Health Organization. Retrieved October 27, 2021, from https://covid19.who.int/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005392/en/

Copyright Business Wire 2021